Mighty Therapeutics Launches New Studies for MYTX-255, a Cutting-Edge Mitochondrial Treatment#United_States#Needham#Mighty_Therapeutics#MYTX-255#mitochondrial_dysfunction
Mighty Therapeutics Launches New Studies for MYTX-255, a Cutting-Edge Mitochondrial Treatment
Mighty Therapeutics embarks on IND-enabling studies for MYTX-255, a groundbreaking therapeutic targeting mitochondrial dysfunction in severe diseases. The company aims for IND submission in 2027.
third-news.com
September 9, 2026 at 1:21 PM
Mighty Therapeutics Launches New Studies for MYTX-255, a Cutting-Edge Mitochondrial Treatment#United_States#Needham#Mighty_Therapeutics#MYTX-255#mitochondrial_dysfunction